Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine

• Published in: American journal of ophthalmology case reports Vol. 23; p. 101136
• Main Authors: Fowler, Nicholas, Mendez Martinez, Noe R., Pallares, Bernardo Velazquez, Maldonado, Ramiro S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2021; Elsevier
• Subjects: Case Report; Central serous retinopathy; COVID-19; CSR; mRNA vaccine; COVID-19; Central serous retinopathy; CSR; mRNA vaccine
• ISSN: 2451-9936; 2451-9936
• DOI: 10.1016/j.ajoc.2021.101136

We report the case of a 33-year-old male who presented with unilateral central serous retinopathy three days after the injection of a COVID-19 vaccine. A 33-year-old healthy Hispanic male referred to the ophthalmology service due to blurry vision and metamorphopsia in the right eye without any flashes, floaters, eye redness or pain. The patient reported that 69 hours prior to presentation he received the first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine. He denied any past ocular history or pertinent medical history. He does not take any medicines and denies stressful factors in his life. The clinical examination and imaging tests were consistent with central serous retinopathy that resolved in three months. This is the first report of an ocular complication potentially associated with a COVID-19 vaccination. Our case contributes information of a side effect potentially related to this new vaccine.